Survival after BFR conditioning for alloSCT. (A) OS and PFS rates after nonmyeloablative allogeneic transplantation with bendamustine, fludarabine, and rituximab conditioning. (B) OS rates by histologic type. (C) OS rates by donor type. FL, follicular lymphoma; MCL, mantle cell lymphoma. DLBCL/TCL, diffuse large B-cell and T-cell lymphoma.